The Ritonavir Price experienced an increasing trajectory during the third quarter of 2022. Ritonavir, a significant pharmaceutical API import, got severely affected by the exporting countries, including China and India, because of zero covid policies imposed in the Chinese market. In the H1 of the third quarter, the price value of Ritonavir API rose considerably, backed by healthy demand from end-user pharmaceutical sectors. Furthermore, towards the termination and start of h3, the prices went down at a steady rate owing to the weaker trader compared to the previous two months in q3. Overall, in the third quarter, the value displayed for Ritonavir was settled at USD 708500/MT CFR Los Angeles in the United States.